DAMORA THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
DAMORA THERAPEUTICS, INC. (DMRA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 25.27 million shares for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-07-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-07-29
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-06-30 was 25.27M shares, a 0.03% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 25.26M shares, a 0.00% change year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 25.26M shares, a 44.26% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 25.26M shares, a 9617.36% increase year-over-year.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 25.26M shares, a 452.45% increase from fiscal 2020.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 4.57M shares, a 1658.96% increase from fiscal 2019.
- DAMORA THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 259.97K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | 25.27M shares 10-Q · filed 2022-07-29 | 25.27M shares 10-Q · filed 2022-07-29 | 25.26M shares derived: average of 3 quarters · filed 2022-07-29 | 25.26M shares derived: average of 4 quarters · filed 2022-07-29 |
| 2022-03-31 | 25.26M shares 10-Q · filed 2022-04-29 | 25.26M shares derived: average of 2 quarters · filed 2022-04-29 | 25.26M shares derived: average of 3 quarters · filed 2022-04-29 | 25.26M shares derived: average of 4 quarters · filed 2022-07-29 |
| 2021-12-31 | 25.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | 25.26M shares derived: average of 2 quarters · filed 2022-02-17 | 25.26M shares derived: average of 3 quarters · filed 2022-07-29 | 25.26M shares 10-K · filed 2022-02-17 |
| 2021-09-30 | 25.26M shares 10-Q · filed 2021-11-04 | 25.26M shares derived: average of 2 quarters · filed 2022-07-29 | 25.26M shares 10-Q · filed 2021-11-04 | 23.32M shares derived: average of 4 quarters · filed 2022-07-29 |
| 2021-06-30 | 25.26M shares 10-Q · filed 2022-07-29 | 25.26M shares 10-Q · filed 2022-07-29 | 22.68M shares derived: average of 3 quarters · filed 2022-07-29 | 17.07M shares derived: average of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | 25.26M shares 10-Q · filed 2022-04-29 | 21.39M shares derived: average of 2 quarters · filed 2022-04-29 | 14.34M shares derived: average of 3 quarters · filed 2022-04-29 | 10.82M shares derived: average of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | 17.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | 8.89M shares derived: average of 2 quarters · filed 2022-02-17 | 6.01M shares derived: average of 3 quarters · filed 2022-02-17 | 4.57M shares 10-K · filed 2022-02-17 |
| 2020-09-30 | 259.97K shares 10-Q · filed 2021-11-04 | 259.97K shares derived: average of 2 quarters · filed 2021-11-04 | 259.97K shares 10-Q · filed 2021-11-04 | 259.97K shares derived: average of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | 259.97K shares 10-Q · filed 2021-08-05 | 259.97K shares 10-Q · filed 2021-08-05 | 259.97K shares derived: average of 3 quarters · filed 2021-08-05 | 259.97K shares derived: average of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | 259.97K shares 10-Q · filed 2021-05-04 | 259.97K shares derived: average of 2 quarters · filed 2021-05-04 | 259.97K shares derived: average of 3 quarters · filed 2021-05-04 | |
| 2019-12-31 | 259.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 259.97K shares derived: average of 2 quarters · filed 2021-03-29 | 259.97K shares 10-K · filed 2021-03-29 | |
| 2019-09-30 | 259.97K shares 10-Q · filed 2020-12-11 | 259.97K shares 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |